CD8A and neoplasm: The combination of p19Arf and IFN-β proved to be an effective immunotherapy since we confirmed the participation of natural killer (NK) cells and CD4+ and CD8+ T-lymphocytes in immune protection against B16-F10 tumor progression [58].